2023 年第一季度报告 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 | | | | --- | --- | --- | --- | --- | | | | 增减变动幅度(%) | | | | 营业收入 | 81,851,831.18 | | | -8.08 | | 归属于上市公司股东的净 | 15,867,632.60 | | | -33.69 | | 利润 | | | | | | 归属于 ...

投资者关系活动记录表 证券代码:688098 公司简称：申联生物 1 编号：2022-001 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------|----------------------------|-------------|------------------------------------------------------------------|-------|------------------------| | | | | | | | | | | √特定对象调研 | | √分析师会议 | | | | | | | | | □媒体采访 □业绩说明会 | | | | 投资者关系活 | | | | □新闻发布会 □路演活动 | | | | 动类别 | □现场参观 | | | | | | | | □其他 | （请文字说明其他活动内容） | | | | | | | 1 、 2022 年 | 6 月 16 日下午 15 | 30 分 | 点 | | | | | | 华安证券 ...

2022 年第三季度报告 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人聂东升、主管会计工作负责人李瑞玲及会计机构负责人（会计主管人员）王琪保证季 度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告 | | --- | --- | --- | --- | --- | | | | 上年同期增 | | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 148,322,330.47 | 24.24 | 286 ...

2022 年半年度报告 申联生物医药（上海）股份有限公司 2022 年半年度报告 三、公司全体董事出席董事会会议。 建设世界一流的高科技生物公司 公司代码：688098 公司简称：申联生物 1/171 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 请参见本报告"第三节管理层讨论与分析"之"五、风险因素"的相关内容，该章节对公司 可能面对的重大风险因素进行了分析和提示，请投资者务必仔细阅读。 √适用 □不适用 本报告中涉及的公司未来经营计划、发展战略、预计/测等前瞻性陈述不构成本公司对投资 者的实质承诺，敬请投资者注意投资风险。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 九、是否存在被控股股东及其关联方非经营性占用资金情况 无 否 七、是否存在公司治理特殊安排等重要事项 十、是否存在违反规定决策程序对外提供担保的情况？ □适用 √不适用 否 八、前瞻性陈述的风险声明 | | 第一节 释义 4 | | --- | --- | ...

Financial Performance - The company's operating revenue for 2021 was CNY 358,429,248.99, representing a 6.13% increase compared to CNY 337,732,400.53 in 2020[23]. - Net profit attributable to shareholders of the listed company decreased by 14.91% to CNY 110,201,862.80 from CNY 129,514,301.93 in the previous year[23]. - The net cash flow from operating activities was CNY 90,119,983.59, down 19.34% from CNY 111,730,338.42 in 2020[23]. - The company's total assets increased by 5.55% to CNY 1,598,464,318.21 at the end of 2021, compared to CNY 1,514,469,447.73 at the end of 2020[23]. - Basic earnings per share decreased by 15.63% to CNY 0.27 in 2021 from CNY 0.32 in 2020[24]. - The gross margin for the main business was 75.69%, down 7.98 percentage points from the previous year[110]. - The company achieved operating revenue of CNY 358.43 million, a year-on-year increase of 6.13%, with the main business revenue being CNY 357.79 million, up 6.05% from the previous year[105]. - Operating costs increased by 57.89% compared to the previous year, primarily due to the formal production and sales of the "Porcine Foot-and-Mouth Disease O-type and A-type Bivalent Inactivated Vaccine," leading to higher depreciation of fixed assets[107]. - The net profit attributable to shareholders was CNY 110.20 million, a decrease of 14.91% year-on-year[104]. - The net cash flow from investment activities worsened by 41.19%, from -90,099,196.87 to -127,210,857.42 RMB[119]. Research and Development - Research and development expenses accounted for 19.14% of operating revenue, an increase of 9.13 percentage points from 10.01% in 2020[24]. - Total R&D investment increased significantly to CNY 68,585,557.93, a 102.94% increase compared to the previous year[69]. - The company has increased its R&D output, with a total of 92 patent applications and 77 granted patents, reflecting its commitment to innovation[68]. - The company has established four major technology platforms, including synthetic peptide vaccine technology and inactivated vaccine technology, enhancing its competitive edge in the industry[78]. - The company is focusing on developing a competitive intellectual property system related to virus-like particle vaccine technology, with multiple proprietary technologies achieved[128]. - The company plans to increase R&D efforts for multivalent and multi-component vaccines to reduce the number of vaccinations required for livestock, addressing new demands in vaccine development[59]. - The company has made significant progress in developing a range of vaccines for swine diseases, including the recombinant foot-and-mouth disease vaccine and the three-in-one inactivated vaccine for swine infectious diseases[130]. Product Development and Innovation - The company successfully launched the new product "Tai Ji Lian," which won the "2021 Annual Influential Foot-and-Mouth Disease Vaccine" award in China[34]. - The company obtained new veterinary drug registration certificates for the bovine foot-and-mouth disease bivalent synthetic peptide vaccine and the porcine circovirus type 2 subunit vaccine[35]. - The company has developed the first domestic bivalent synthetic peptide vaccine for foot-and-mouth disease (FMD) in pigs, consisting of peptides 2700+2800+MM13[60]. - The company has successfully developed a bivalent inactivated vaccine for foot-and-mouth disease, which has received a first-class new veterinary drug registration certificate and is recognized for its high immunogenicity and protection[83]. - The company is actively developing other inactivated vaccines, including a subunit vaccine for porcine circovirus type 2, which is currently in trial production[65]. - The company has completed trial production of diagnostic kits for African swine fever and FMD, with ongoing efforts to obtain product approval numbers[67]. Market Position and Strategy - The company ranked fifth in the domestic pig biological products market with a sales amount of 338 million yuan in 2020, representing a market share of 4.88%[53]. - The company is actively expanding its product line, with ongoing projects for vaccines against porcine infectious gastroenteritis and porcine epidemic diarrhea[35]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[106]. - The company aims to focus on high-end markets and develop vaccines for major diseases affecting livestock, including foot-and-mouth disease and African swine fever[154]. - The company plans to launch a bivalent inactivated vaccine for foot-and-mouth disease, adjusting sales strategies to prioritize market sales over government procurement[155]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Dahua Certified Public Accountants, ensuring the accuracy of its financial statements[6]. - The company’s board of directors and management have confirmed the authenticity and completeness of the annual report, ensuring transparency[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity[8]. - The company has not violated decision-making procedures for external guarantees, maintaining compliance with regulations[8]. - The company emphasizes the importance of risk factors in its future operations, urging investors to carefully consider potential risks[7]. - The company strictly adheres to corporate governance regulations, ensuring the protection of shareholder rights and the effective operation of its governance structure[163]. Talent Development and Human Resources - The company has established a comprehensive talent development and incentive system to enhance team capabilities and cohesion[38]. - The R&D team consists of 69 members, accounting for 23.23% of the total workforce, with expertise in various fields such as biological engineering and veterinary medicine[88]. - The company aims to optimize its compensation incentive system to enhance employee motivation and creativity, conducting external salary surveys to ensure competitiveness[197]. - The company established the Shunlian Training Center in June 2021 to focus on employee growth and development, offering systematic learning environments[198]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting revenue growth of 25% to $625 million[174]. - The company plans to increase its marketing budget by 30% to support new product launches and market expansion efforts[176]. - Overall, the company remains optimistic about future growth, driven by strong user engagement and innovative product offerings[174].

2022 年第一季度报告 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人聂东升、主管会计工作负责人李瑞玲及会计机构负责人（会计主管人员）王琪保证季 度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 12 单位：元 币种：人民币 项目 本报告期 本报告期比上年同 期增减变动幅度(%) 营业收入 89,049,518.25 7.48 归属于上市公司股东的净利润 23,928,559.11 -15.7 归属于上市公司股东的扣除非经 常性损益的净利润 20,331,229.47 -18.85 经营活动产生的现金流量净额 -42,272,933.50 -2.68 基本 ...

2021 年第三季度报告 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 项目 | 本报告期 | 本报告期比上 | | 年初至报告期末 | | | --- | --- | --- | --- | --- | --- | | | | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | | 动幅度(%) | | 变动幅度(%) | | | 营业收入 | 119,387,375.73 | -19.08 | 272,415,976.87 | | -9.84 | | 归属于上市公司股东的净 利润 | 47,470,138.97 | -38.09 | 91,891,168.73 | | -33.13 | | 归属于上市公司股东的扣 | 43,604,297.37 | -39.11 | 82,120,554.21 | | -32.44 | | 除非经常性损益的净利润 | | | | | | | 经营活动产生的现金 ...

2021 年半年度报告 公司代码：688098 公司简称：申联生物 申联生物医药（上海）股份有限公司 2021 年半年度报告 建设世界一流的高科技生物公司 1 / 184 2021 年半年度报告 重要提示 □适用 √不适用 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 八、前瞻性陈述的风险声明 请参见本报告"第三节 管理层讨论与分析"之"五、风险因素"的相关内容，该章节对公司可能面 对的重大风险因素进行了分析和提示，请投资者务必仔细阅读。 三、公司全体董事出席董事会会议。 四、本半年度报告未经审计。 五、公司负责人聂东升、主管会计工作负责人李瑞玲及会计机构负责人（会计主管人员）王琪声明：保证 半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 √适用 □不适用 本报告中涉及的公司未来经营计划、发展战略、预计/测等前瞻性陈述不构成本公司对投资者的实质 承诺，敬请投资者注意投资风险。 九、是 ...

2021 年第一季度报告 公司代码：688098 公司简称：申联生物 申联生物医药（上海）股份有限公司 2021 年第一季度报告 1 / 23 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 7 | | 四、 | 附录 10 | 2021 年第一季度报告 一、重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 √适用 □不适用 3 / 23 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 1,531,087,711.10 1,514,469,447.73 1.10 归属于上市公司股东的净资产 1,429,203,891.03 1,396,412,887.45 2.35 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现金流量净额 -43,438,746.69 -12,704,566.96 -241.91 年初至报 ...

Financial Performance - The company's operating revenue for 2020 was approximately CNY 337.73 million, representing a year-over-year increase of 33.07% compared to CNY 253.81 million in 2019[22]. - Net profit attributable to shareholders for 2020 was approximately CNY 129.51 million, a significant increase of 66.14% from CNY 77.96 million in 2019[22]. - The basic earnings per share for 2020 was CNY 0.32, reflecting a growth of 52.38% compared to CNY 0.21 in 2019[24]. - The company's cash flow from operating activities for 2020 was approximately CNY 111.73 million, which is a remarkable increase of 107.63% from CNY 53.81 million in 2019[22]. - The total net assets attributable to shareholders at the end of 2020 were approximately CNY 1.40 billion, an increase of 8.98% from CNY 1.28 billion at the end of 2019[22]. - The company's operating cash flow net amount was CNY 111.73 million, a significant increase of 107.63% from CNY 53,812,891.77 in the previous year[100]. - The company achieved a revenue of 338 million yuan in 2020, representing a year-on-year growth of 33.07%, while net profit increased by 66.14% compared to the previous year[78]. - The main business revenue from veterinary biological products was CNY 337.39 million, up 32.99% year-on-year[101]. - The gross margin for veterinary biological products improved by 1.39 percentage points to 83.67%[103]. Research and Development - Research and development expenses accounted for 10.01% of operating revenue in 2020, a slight decrease of 0.46 percentage points from 10.47% in 2019[24]. - R&D investment totaled approximately ¥33.8 million, a 27.22% increase from the previous year, with R&D expenses accounting for 10.01% of revenue[60]. - The company has filed for 10 new patents during the reporting period, bringing the total number of patents to 80, including 34 invention patents[59]. - The company is actively engaged in the research and development of multi-valent vaccines to reduce the number of vaccinations required for livestock, thereby alleviating the burden on farmers[52]. - The company has established multiple core technology platforms, including synthetic peptide vaccine technology, inactivated vaccine technology, and virus-like particle vaccine technology, enhancing its R&D capabilities[54]. - The R&D team includes 67 members with diverse expertise in animal immunology, veterinary medicine, and molecular biology, providing a solid foundation for innovation[75]. - The company plans to significantly increase R&D investment in 2021, focusing on new vaccine development and maintaining its competitive edge in the industry[87]. - The company is focusing on expanding its product pipeline in both vaccines and diagnostics, enhancing its competitive position in the market[58]. Market Position and Strategy - The company ranks first in the domestic market share for swine foot-and-mouth disease synthetic peptide vaccines, maintaining a leading position in this segment[50]. - The company is a designated producer of foot-and-mouth disease vaccines, adhering to a "prevention first" policy, with vaccines being mandatory for immunization[34]. - The veterinary biological products industry in China is experiencing a steady growth trend, with the market expected to recover following the impacts of African swine fever and COVID-19[41]. - The company plans to enhance its marketing network and brand promotion, targeting mid-to-high-end markets and adopting differentiated sales strategies for various customer segments[153]. - The company aims to become a world-class high-tech biological company, focusing on foot-and-mouth disease vaccines and expanding into other vaccine and diagnostic product areas[150]. Governance and Compliance - The company has established a comprehensive governance structure with all board members present at the board meeting[6]. - The company operates under the supervision of the China Securities Regulatory Commission and the Shanghai Stock Exchange[11]. - The company emphasizes strict compliance with industry regulations to avoid risks related to production and operational licenses[90]. - The company has committed to enhancing its governance structure to ensure that shareholders can fully exercise their rights and that the board of directors operates according to legal and regulatory requirements[186]. - The company has confirmed compliance with legal regulations regarding stock trading by its general manager[195]. Risk Management - The company emphasizes the importance of risk awareness regarding future operational plans and development strategies, indicating that forward-looking statements do not constitute a commitment to investors[8]. - The company faces risks related to the relocation of its synthetic peptide vaccine production line, which may impact sales revenue in 2021 if regulatory approvals are delayed[88]. - The company has implemented comprehensive biosecurity measures to manage risks associated with vaccine production[91]. - The company faces potential risks related to product quality management as it expands its operations[92]. - Environmental protection risks are present due to the company's classification as a key pollutant discharge unit[93]. Profit Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 40,970,000 RMB (including tax) based on a total share capital of 409,700,000 shares as of December 31, 2020[7]. - In 2020, the company distributed cash dividends amounting to 40,970,000 RMB, which represented 31.63% of the net profit attributable to ordinary shareholders[164]. - The company's profit distribution policy allows for cash dividends of at least 20% of the distributable profit for the year, provided certain conditions are met[159]. - The company has not proposed any cash profit distribution plan despite having positive distributable profits during the reporting period[165]. - The company has a policy to ensure that retained undistributed profits are primarily used for working capital and expanding production capacity[162]. Audit and Compliance - The company has received a standard unqualified audit report from Dahua Certified Public Accountants[6]. - The company appointed Da Hua Accounting Firm as the external auditor for the 2020 fiscal year, with an audit fee of RMB 400,000 and an internal control audit fee of RMB 200,000, totaling RMB 600,000[199]. - There were no significant litigation or arbitration matters reported for the year[200]. - The company has not disclosed any major lawsuits or arbitration cases during the reporting period[200].